Rezvilutamide after prostate removal for high-risk cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if a daily pill called Rezvilutamide can prevent prostate cancer from returning in men who had their prostate removed and are at high risk of recurrence. It is for men who cannot or choose not to have radiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 to 75 with prostate cancer that has not spread beyond the prostate.
- You had your prostate removed within the past 12 weeks and your PSA level is very low (under 0.1 ng/mL) after surgery.
- Your cancer has a high risk of coming back, as shown by a CAPRA-S score of 6 or more.
- You are in good general health (able to perform daily activities) and your liver, kidneys, and blood counts meet required levels.
- You have not received hormone therapy, chemotherapy, or radiation for prostate cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This Phase 2 study tests whether adding apalutamide to standard hormone therapy (ADT) after prostate surgery can lower the chance that prostate cancer comes back. It targets men at higher risk of recurrence based on PSA levels and a risk score from surgical findings.
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
This trial tests a new drug called Rezvilutamide in men who have had surgery for high-risk prostate cancer and are not getting radiation therapy. The goal is to see if the drug can help prevent the cancer from coming back.
Hear when a new Prostate Cancer (Post Prostatectomy) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.